Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
NCT ID: NCT02735707
Last Updated: 2024-07-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
20000 participants
INTERVENTIONAL
2016-04-11
2028-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia.
In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19.
REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19 in the United States of America.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Arterio-venous ECMO on Severe Sepsis and ARDS
NCT04555798
Pulmonary Inflammation in COVID-19 ARDS
NCT04935450
ClusterVAP: Multicentre Proteomic Endotyping of Ventilator-associated Pneumonia
NCT07245888
Risks Factors and Outcome of Recurrences in Patients With Ventilator-Associated Pneumonias (REVAP)
NCT06066736
Diagnostic and Prognostic Value of Reticulated Platelet Fraction in Ventilator-Associated Pneumonia (REPLAY-VAP)
NCT07013032
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients with pneumonia who are being treated in an ICU will receive therapy that consists of many different treatments, as many as 20 or 30. These treatments act together to treat both the infection and its effects on the body. When treating a patient, doctors choose from many different treatments, most of which are known or believed to be safe and effective. However, doctors don't always know which treatment option is the better one, as individuals or groups of individuals may respond differently. This study aims to help doctors understand which treatments work best.
This clinical study has been designed in a way that allows the information from patients already in the study to help new patients joining the study. Most studies aren't able to do that. REMAP-CAP has been designed to:
* Evaluate multiple treatment strategies, at the same time, in the same patient.
* Reach platform conclusions when sufficient data is accrued, rather than when a pre-specified sample size is reached
* Utilise data that is already accrued to increase the likelihood that patients within the trial are randomised to treatments that are more likely to be beneficial
* New questions can be substituted into the trial as initial questions are answered, meaning that the trial can be perpetual or open-ended
* Interactions between interventions in different domains can be evaluated
It is reasonable to presume that any pandemic respiratory infection of major significance to public health will manifest as life-threatening respiratory infection including Severe Acute Respiratory illness and severe Community Acquired Pneumonia (CAP) with concomitant admission to hospital, and for some patients, admission to an Intensive Care Unit (ICU). Previous pandemics and more localized outbreaks of respiratory emerging infections have resulted in severe CAP and ICU admission.
Previous pandemics and outbreaks of emerging infectious diseases have outlined the urgent need for evidence, preferably from Randomized Controlled Trials (RCTs), to guide best treatment. However, there are substantial challenges associated with being able to organize such trials when the time of onset of a pandemic and its exact nature are unpredictable. As an adaptive platform trial that enrolls patients during the interpandemic period, REMAP-CAP is ideally positioned to adapt, in the event of a respiratory pandemic, to evaluate existing treatments as well as novel approaches.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Antibiotic Domain
Patients with community-acquired pneumonia admitted to participating intensive care units and requiring empiric antibiotic therapy will be randomised one of five antibiotic interventions.
Note: the ceftaroline + macrolide intervention has been closed to recruitment.
Ceftriaxone
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
Moxifloxacin or Levofloxacin
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
Piperacillin-tazobactam
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
Ceftaroline
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
Note: this intervention is now closed.
Amoxicillin-clavulanate
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
Macrolide Duration Domain
Patients with community-acquired pneumonia admitted to participating intensive care units who have been allocated to a beta-lactam antibiotic intervention in the Antibiotic Domain will be randomised to either a standard course or extended course of macrolide therapy
Standard course macrolide
Standard course of macrolide therapy, discontinued between study day 3 and the end of study day 5.
The dosing of and route of administration is not protocolised, the following guidance is provided:
* Initial IV administration of a macrolide is strongly preferred
* The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted.
* The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted.
Extended course macrolide
Extended course of macrolide therapy discontinued at the end of study day 14 or hospital discharge (whichever occurs first).
The dosing of and route of administration is not protocolised, the following guidance is provided:
* Initial IV administration of a macrolide is strongly preferred
* The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted.
* The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted.
Corticosteroid Domain
Patients with community acquired pneumonia (CAP) admitted to participating hospitals will be randomised to a steroid use strategy.
Note: this domain is now closed to patients with suspected or proven COVID-19. It remains open to patients with CAP without COVID-19.
Note: the fixed-course hydrocortisone has been closed to recruitment
No systemic corticosteroid
Patients are not to receive any systemic corticosteroids, including hydrocortisone, to study day 28 or hospital discharge (whichever occurs first).
Fixed-duration Hydrocortisone
50mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days.
Note: this intervention is now closed.
Shock-dependent hydrocortisone
50mg IV hydrocortisone every 6 hours while the patient is in septic shock
Fixed-duration higher dose Hydrocortisone
100mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days.
Note: this intervention was only available to patients with suspected or proven COVID-19 and is now closed.
Fixed-duration dexamethasone
6 mg of IV or enteral dexamethasone will be administered daily for up to 10 days while in hospital.
Influenza Antiviral Domain
Patients with community-acquired pneumonia admitted to participating hospitals with microbiological testing confirmed influenza infection will be randomised to one of six interventions.
No antiviral agent for influenza
No antiviral agent intended to be active against influenza infection is to be administered
Five-days oseltamivir
Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first)
Ten-days oseltamivir
Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first)
Baloxavir Marboxil
Baloxavir marboxil administered on days 1 and 4 post-randomisation.
Five-days oseltamivir + baloxavir marboxil
Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first), in addition to baloxavir marboxil administered on days 1 and 4 post-randomisation.
Ten-days oseltamivir + baloxavir marboxil
Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first), in addition to baloxavir marboxil administered on days 1 and 4 post-randomisation.
COVID-19 Antiviral Domain
Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to no ivermectin or ivermectin.
Note: an earlier version of this domain evaluated lopinavir-ritonavir, hydroxychloroquine, and combination lopinavir-ritonavir and hydroxychloroquine against a 'no antiviral' control.
This domain is now closed.
No antiviral agent for COVID-19
No antiviral agent intended to be active against SARS-CoV-2 infection is to be administered
Lopinavir / Ritonavir
Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU.
Note: this intervention is now closed.
Hydroxychloroquine
Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first).
Note: this intervention is now closed.
Hydroxychloroquine + lopinavir/ritonavir
Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU.
Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first).
Note: this intervention is now closed.
Ivermectin
Ivermectin administered enterally at a dose of 0.2 mg/kg once daily with a maximum daily dose of 24mg/day.
Note: this intervention is now closed.
COVID-19 Immune Modulation Domain
Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to one of up to five interventions.
Note: this domain is now closed.
No immune modulation for COVID-19
No immune modulating agent intended to be active against COVID-19 is to be administered.
Note: this intervention is now closed.
Interferon beta-1a
IFN-β1a 10 μg will be administered as an intravenous bolus injection via a central or peripheral line. IFN-β1a will be administered once daily for 6 days or until ICU discharge, whichever occurs first.
Note: this intervention is now closed.
Anakinra
A loading dose of 300mg anakinra will be administered as a bolus via central or peripheral line. This is followed by maintenance doses of 100mg of anakinra administered every 6 hours.
In patients with renal impairment, anakinra will be administered on alternate days.
Note: this intervention is now closed.
Tocilizumab
Tocilizumab will be administered as a single dose of 8mg/kg estimated or measured body weight, with a maximum total dose of 800mg.
Tocilizumab will be administered as an IV infusion via central or peripheral line over a one-hour period.
Note: this intervention is now closed.
Sarilumab
Sarilumab will be administered as a single dose of 400mg, via IV infusion through peripheral or central line over a one-hour period.
Note: this intervention is now closed.
Anticoagulation Domain
Patients admitted to participating intensive care units with suspected or microbiological testing confirmed COVID-19 will be randomised to an anticoagulation strategy.
Note: A previous version of this domain evaluated local standard venous thromboprophylaxis against therapeutic dose anticoagulation. This domain is now closed.
Local standard venous thromboprophylaxis
Standard venous thromboprophylaxis that complies with local guidelines or usual practice will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first.
Note: this intervention is now closed.
Therapeutic dose anticoagulation
Patients will be administered either low molecular weight heparin (LMWH) or unfractionated heparin (UFH) to achieve systemic anticoagulation. Either agent may be used and the same patient may be switched between UFH and LMWH at the discretion of the treating clinician.
Note: this intervention is now closed.
Conventional low dose thromboprophylaxis
Low dose thromboprophylaxis will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Dosing is outlined in the relevant protocol documents for this domain.
Intermediate dose thromboprophylaxis
Intermediate dose thromboprophylaxis will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Dosing is outlined in the relevant protocol documents for this domain.
Continuation of therapeutic dose anticoagulation
Patients already receiving therapeutic dose anticoagulation at the time of randomisation to this intervention will be administered either unfractionated heparin by IV infusion or low-molecular weight heparin to achieve systemic anticoagulation according to local practice for acute VTE treatment for 14 days following randomisation or until hospital discharge, whichever occurs first.
Note: this intervention is now closed.
Immunoglobulin Domain
Immunosuppressed patients admitted to participating hospitals with microbiological testing confirmed COVID-19 will be randomised to receive no immunoglobulin for COVID-19, or to receive high-titre convalescent plasma.
Note: an earlier version of this domain was not restricted to immunosuppressed patients.
No immunoglobulin
No immunoglobulin intended to be active against SARS-CoV-2 infection is to be administered.
Convalescent plasma
Patients will receive at least one and no more than two units of ABO compatible convalescent plasma within 48 hours of randomisation.
Delayed administration of convalescent plasma
Note: this intervention is now closed.
Vitamin C Domain
Patients admitted to participating hospitals with community-acquired pneumonia will be randomised to receive no vitamin C, or vitamin C.
Note: this domain is now closed.
No vitamin C
No high dose intravenous vitamin C is to be administered
Note: this intervention is now closed.
Vitamin C
Intravenous Vitamin C 50mg/kg administered every 6 hours for 16 doses
Note: this intervention is now closed.
Simvastatin Domain
Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to receive no simvastatin, or simvastatin.
Note: this domain is now closed.
No simvastatin
No simvastatin intended to be active against COVID-19 is to be administered
Note: this intervention is now closed.
Simvastatin
Simvastatin 80mg administered once daily via enteral route, while the patient remains in hospital up to 28 days after randomisation
Note: this intervention is now closed.
Antiplatelet Domain
Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to receive no antiplatelet, aspirin, or site-preferred P2Y12 inhibitor.
Note: this domain is now closed.
No antiplatelet
No antiplatelet agent or NSAID to be administered.
Note: this intervention is now closed.
Aspirin
Aspirin administered at either 75mg or 100mg once per day for 14 days or until hospital discharge, whichever occurs first.
Note: this intervention is now closed.
P2Y12 inhibitor
Site-selected P2Y12 inhibitor:
* Clopidogrel: administered 75 mg once per day for 14 days or until hospital discharge, whichever occurs first.
* Prasugrel: If patient is aged less than 75 years and measured or estimated weight if 60kg or more, and initial loading dose of prasugrel 60 mg will be administered, followed by maintenance dose of 10 mg per day.
* Ticagrelor: administered enterally at 60mg twice daily for 14 days or until hospital discharge, whichever occurs first.
Note: this intervention is now closed.
Mechanical Ventilation Domain
Patients with community-acquired pneumonia admitted to participating intensive care units who are intubated and receiving invasive mechanical ventilation will be randomised to protocolised mechanical ventilation strategy, or clinician-preferred mechanical ventilation strategy
Clinician-preferred mechanical ventilation strategy
Clinician-preferred ventilation strategy, including mode of ventilation and all ventilatory parameters
Protocolised mechanical ventilation strategy
Invasive mechanical ventilation strategy delivered as outlined in relevant protocol documents for this domain.
COVID-19 Immune Modulation (2) Domain
Patients admitted to participating hospitals with microbiological testing confirmed COVID-19 will be randomised to receive one of three interventions.
Note: this domain is now closed.
No immune modulation for COVID-19
No immune modulating agent intended to be active against COVID-19 is to be administered.
Note: this intervention is now closed.
Eritoran
Eritoran initiated with a 26.24 mg loading dose (6.56 mg/h IV for 4 hours), followed by a second 13.12 mg loading dose (6.56 mg/h IV for 2 hours) at 12 hours after initiation. Patients will then receive twenty-six 6.56 mg maintenance doses (3.28 mg/h IV for 2 hours) every 12 hours thereafter (total of 14 days). Dosing will be stopped if the patient is discharged from hospital
Note: this intervention is now closed.
Apremilast
Apremilast administered 30mg twice daily for 14 days or until hospital discharge, whichever occurs first.
Note: this intervention is now closed.
ACE2 RAS Domain
Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to one of up to five renin-angiotensin system blockade strategies.
Note: this domain is now closed.
No renin-angiotensin system inhibitor
No RAS inhibitor (i.e. no ACEi or ARB) is to be administered up to the end of study day 10.
Note: this intervention is now closed.
Angiotensin converting enzyme inhibitor
Site-preferred ACEi agent administered as directed by the treating clinician for 10 days or until hospital discharge, whichever occurs first.
Note: this intervention is now closed.
Angiotensin Receptor Blockers
Site-preferred ARB agent administered as directed by the treating clinician for 10 days or until hospital discharge, whichever occurs first.
Note: this intervention is now closed.
ARB + DMX-200
Site-preferred ARB agent administered in combination with DMX-200 for 10 days or until hospital discharge, whichever occurs first.
ARB administered as directed by the treating clinician. DMX-200 administered enterally at a dose of 120mg twice daily.
Note: this intervention is now closed.
Cysteamine Domain
Patients admitted to participating hospitals with severe community-acquired pneumonia, including patients with suspected or proven influenza or COVID-19, will be randomised to receive no cysteamine, or cysteamine.
Note: this domain is now closed.
No cysteamine
No cysteamine to be administered until the end of study day 10 or hospital discharge, whichever occurs first.
Note: this intervention is now closed.
Cysteamine
Cysteamine administered every 8 hours at a dose of 5 mg/kg estimated or measured body weight (maximum dose of 500mg), for ten days or until ICU discharge, whichever occurs first.
Note: this intervention is now closed.
Endothelial Domain
Patients admitted to participating hospitals with severe community-acquired pneumonia, including patients with suspected or proven influenza or COVID-19, will be randomised to receive no endothelial modulator or enteral imatinib.
No endothelial modulator
No endothelial modulator (imatinib or another tyrosine kinase inhibitor targeting the same pathway as imatinib) is to be administered.
Imatinib
Enteral imatinib will be administered as a single 800mg loading dose (study day 1) followed by 400mg daily until study day 14 or discharge.
Influenza Immune Modulation
Patients with community-acquired pneumonia admitted to participating intensive care units with microbiological testing confirmed influenza infection will be randomised to one of three interventions.
No Immune Modulator for Influenza
No immune modulating agent intended to be active against influenza is to be administered.
Tocilizumab
Tocilizumab will be administered as a single dose of 8mg/kg estimated or measured body weight, with a maximum total dose of 800mg. In children weighing less than 30kg, tocilizumab dose will be 12mg/kg.
Tocilizumab will be administered as an IV infusion via central or peripheral line over a one-hour period.
Baricitinib
Baricitinib will be administered at a dose that is determined by age and renal function, for up to 10 days or hospital discharge (whichever occurs first).
COVID-19 Antiviral (II) Domain
Patients admitted to participating hospitals with microbiological testing confirmed COVID-19 will be randomised to one of up to four interventions.
No antiviral agent for COVID-19
No antiviral agent intended to be active against SARS-CoV-2 infection is to be administered
Nirmatrelvir/ritonavir
Nirmatrelvir-ritonavir will be administered at a dose that is dependent on renal function, for five days.
Remdesivir
Remdesivir is administered at 200 mg on day one followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first.
Nirmatrelvir/ritonavir + remdesivir
Nirmatrelvir-ritonavir will be administered at a dose that is dependent on renal function, for five days. Remdesivir is administered at 200 mg on day one followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ceftriaxone
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
Moxifloxacin or Levofloxacin
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
Piperacillin-tazobactam
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
Ceftaroline
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
Note: this intervention is now closed.
Amoxicillin-clavulanate
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
Standard course macrolide
Standard course of macrolide therapy, discontinued between study day 3 and the end of study day 5.
The dosing of and route of administration is not protocolised, the following guidance is provided:
* Initial IV administration of a macrolide is strongly preferred
* The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted.
* The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted.
Extended course macrolide
Extended course of macrolide therapy discontinued at the end of study day 14 or hospital discharge (whichever occurs first).
The dosing of and route of administration is not protocolised, the following guidance is provided:
* Initial IV administration of a macrolide is strongly preferred
* The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted.
* The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted.
No systemic corticosteroid
Patients are not to receive any systemic corticosteroids, including hydrocortisone, to study day 28 or hospital discharge (whichever occurs first).
Fixed-duration Hydrocortisone
50mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days.
Note: this intervention is now closed.
Shock-dependent hydrocortisone
50mg IV hydrocortisone every 6 hours while the patient is in septic shock
Fixed-duration higher dose Hydrocortisone
100mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days.
Note: this intervention was only available to patients with suspected or proven COVID-19 and is now closed.
No antiviral agent for influenza
No antiviral agent intended to be active against influenza infection is to be administered
Five-days oseltamivir
Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first)
Ten-days oseltamivir
Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first)
No antiviral agent for COVID-19
No antiviral agent intended to be active against SARS-CoV-2 infection is to be administered
Lopinavir / Ritonavir
Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU.
Note: this intervention is now closed.
Hydroxychloroquine
Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first).
Note: this intervention is now closed.
Hydroxychloroquine + lopinavir/ritonavir
Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU.
Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first).
Note: this intervention is now closed.
Ivermectin
Ivermectin administered enterally at a dose of 0.2 mg/kg once daily with a maximum daily dose of 24mg/day.
Note: this intervention is now closed.
No immune modulation for COVID-19
No immune modulating agent intended to be active against COVID-19 is to be administered.
Note: this intervention is now closed.
Interferon beta-1a
IFN-β1a 10 μg will be administered as an intravenous bolus injection via a central or peripheral line. IFN-β1a will be administered once daily for 6 days or until ICU discharge, whichever occurs first.
Note: this intervention is now closed.
Anakinra
A loading dose of 300mg anakinra will be administered as a bolus via central or peripheral line. This is followed by maintenance doses of 100mg of anakinra administered every 6 hours.
In patients with renal impairment, anakinra will be administered on alternate days.
Note: this intervention is now closed.
Tocilizumab
Tocilizumab will be administered as a single dose of 8mg/kg estimated or measured body weight, with a maximum total dose of 800mg.
Tocilizumab will be administered as an IV infusion via central or peripheral line over a one-hour period.
Note: this intervention is now closed.
Sarilumab
Sarilumab will be administered as a single dose of 400mg, via IV infusion through peripheral or central line over a one-hour period.
Note: this intervention is now closed.
Local standard venous thromboprophylaxis
Standard venous thromboprophylaxis that complies with local guidelines or usual practice will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first.
Note: this intervention is now closed.
Therapeutic dose anticoagulation
Patients will be administered either low molecular weight heparin (LMWH) or unfractionated heparin (UFH) to achieve systemic anticoagulation. Either agent may be used and the same patient may be switched between UFH and LMWH at the discretion of the treating clinician.
Note: this intervention is now closed.
Conventional low dose thromboprophylaxis
Low dose thromboprophylaxis will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Dosing is outlined in the relevant protocol documents for this domain.
Intermediate dose thromboprophylaxis
Intermediate dose thromboprophylaxis will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Dosing is outlined in the relevant protocol documents for this domain.
Continuation of therapeutic dose anticoagulation
Patients already receiving therapeutic dose anticoagulation at the time of randomisation to this intervention will be administered either unfractionated heparin by IV infusion or low-molecular weight heparin to achieve systemic anticoagulation according to local practice for acute VTE treatment for 14 days following randomisation or until hospital discharge, whichever occurs first.
Note: this intervention is now closed.
No immunoglobulin
No immunoglobulin intended to be active against SARS-CoV-2 infection is to be administered.
Convalescent plasma
Patients will receive at least one and no more than two units of ABO compatible convalescent plasma within 48 hours of randomisation.
Delayed administration of convalescent plasma
Note: this intervention is now closed.
No vitamin C
No high dose intravenous vitamin C is to be administered
Note: this intervention is now closed.
Vitamin C
Intravenous Vitamin C 50mg/kg administered every 6 hours for 16 doses
Note: this intervention is now closed.
No antiplatelet
No antiplatelet agent or NSAID to be administered.
Note: this intervention is now closed.
Aspirin
Aspirin administered at either 75mg or 100mg once per day for 14 days or until hospital discharge, whichever occurs first.
Note: this intervention is now closed.
P2Y12 inhibitor
Site-selected P2Y12 inhibitor:
* Clopidogrel: administered 75 mg once per day for 14 days or until hospital discharge, whichever occurs first.
* Prasugrel: If patient is aged less than 75 years and measured or estimated weight if 60kg or more, and initial loading dose of prasugrel 60 mg will be administered, followed by maintenance dose of 10 mg per day.
* Ticagrelor: administered enterally at 60mg twice daily for 14 days or until hospital discharge, whichever occurs first.
Note: this intervention is now closed.
No simvastatin
No simvastatin intended to be active against COVID-19 is to be administered
Note: this intervention is now closed.
Simvastatin
Simvastatin 80mg administered once daily via enteral route, while the patient remains in hospital up to 28 days after randomisation
Note: this intervention is now closed.
Eritoran
Eritoran initiated with a 26.24 mg loading dose (6.56 mg/h IV for 4 hours), followed by a second 13.12 mg loading dose (6.56 mg/h IV for 2 hours) at 12 hours after initiation. Patients will then receive twenty-six 6.56 mg maintenance doses (3.28 mg/h IV for 2 hours) every 12 hours thereafter (total of 14 days). Dosing will be stopped if the patient is discharged from hospital
Note: this intervention is now closed.
Apremilast
Apremilast administered 30mg twice daily for 14 days or until hospital discharge, whichever occurs first.
Note: this intervention is now closed.
Clinician-preferred mechanical ventilation strategy
Clinician-preferred ventilation strategy, including mode of ventilation and all ventilatory parameters
Protocolised mechanical ventilation strategy
Invasive mechanical ventilation strategy delivered as outlined in relevant protocol documents for this domain.
No renin-angiotensin system inhibitor
No RAS inhibitor (i.e. no ACEi or ARB) is to be administered up to the end of study day 10.
Note: this intervention is now closed.
Angiotensin converting enzyme inhibitor
Site-preferred ACEi agent administered as directed by the treating clinician for 10 days or until hospital discharge, whichever occurs first.
Note: this intervention is now closed.
Angiotensin Receptor Blockers
Site-preferred ARB agent administered as directed by the treating clinician for 10 days or until hospital discharge, whichever occurs first.
Note: this intervention is now closed.
ARB + DMX-200
Site-preferred ARB agent administered in combination with DMX-200 for 10 days or until hospital discharge, whichever occurs first.
ARB administered as directed by the treating clinician. DMX-200 administered enterally at a dose of 120mg twice daily.
Note: this intervention is now closed.
No cysteamine
No cysteamine to be administered until the end of study day 10 or hospital discharge, whichever occurs first.
Note: this intervention is now closed.
Cysteamine
Cysteamine administered every 8 hours at a dose of 5 mg/kg estimated or measured body weight (maximum dose of 500mg), for ten days or until ICU discharge, whichever occurs first.
Note: this intervention is now closed.
Fixed-duration dexamethasone
6 mg of IV or enteral dexamethasone will be administered daily for up to 10 days while in hospital.
Baloxavir Marboxil
Baloxavir marboxil administered on days 1 and 4 post-randomisation.
Five-days oseltamivir + baloxavir marboxil
Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first), in addition to baloxavir marboxil administered on days 1 and 4 post-randomisation.
Ten-days oseltamivir + baloxavir marboxil
Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first), in addition to baloxavir marboxil administered on days 1 and 4 post-randomisation.
No endothelial modulator
No endothelial modulator (imatinib or another tyrosine kinase inhibitor targeting the same pathway as imatinib) is to be administered.
Imatinib
Enteral imatinib will be administered as a single 800mg loading dose (study day 1) followed by 400mg daily until study day 14 or discharge.
No Immune Modulator for Influenza
No immune modulating agent intended to be active against influenza is to be administered.
Tocilizumab
Tocilizumab will be administered as a single dose of 8mg/kg estimated or measured body weight, with a maximum total dose of 800mg. In children weighing less than 30kg, tocilizumab dose will be 12mg/kg.
Tocilizumab will be administered as an IV infusion via central or peripheral line over a one-hour period.
Baricitinib
Baricitinib will be administered at a dose that is determined by age and renal function, for up to 10 days or hospital discharge (whichever occurs first).
No antiviral agent for COVID-19
No antiviral agent intended to be active against SARS-CoV-2 infection is to be administered
Nirmatrelvir/ritonavir
Nirmatrelvir-ritonavir will be administered at a dose that is dependent on renal function, for five days.
Remdesivir
Remdesivir is administered at 200 mg on day one followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first.
Nirmatrelvir/ritonavir + remdesivir
Nirmatrelvir-ritonavir will be administered at a dose that is dependent on renal function, for five days. Remdesivir is administered at 200 mg on day one followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. symptoms or signs or both that are consistent with lower respiratory tract infection AND
2. Radiological evidence of new onset consolidation (in patients with pre-existing radiological changes, evidence of new infiltrate)
2. Up to 48 hours after ICU admission, receiving organ support with one or more of:
1. Non-invasive or Invasive ventilatory support;
2. Receiving infusion of vasopressor or inotropes or both
1\. Adult patients (≥ 18 years) admitted to hospital with acute illness due to suspected or proven pandemic infection.
Exclusion Criteria
1. Prior to this illness, is known to have been an inpatient in any healthcare facility within the last 30 days
2. Resident of a nursing home or long term care facility
2. Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment
3. Previous participation in this REMAP within the last 90 days
1. Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment
2. Patient is expected to be discharged from hospital today or tomorrow
3. More than 14 days have elapsed while admitted to hospital with symptoms of an acute illness due to suspected or proven pandemic infection.
4. Previous participation in this REMAP within the last 90 days
DOMAIN-SPECIFIC ELIGIBLE CRITERIA:
Each domain may have additional eligibility criteria. Refer to the study website for more information (www.remapcap.org).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Australian and New Zealand Intensive Care Research Centre
OTHER
Medical Research Institute of New Zealand
OTHER
Unity Health
OTHER
Berry Consultants
OTHER
Global Coalition for Adaptive Research
OTHER
University of Pittsburgh Medical Center
OTHER
Intensive Care National Audit & Research Centre
OTHER
St. Marianna University School of Medicine
OTHER
Nat Intensive Care Surveillance - MORU
OTHER
National University Hospital, Singapore
OTHER
UMC Utrecht
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lennie Derde
Dr.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Steve Webb, Prof
Role: STUDY_CHAIR
Monash University, Study Chair REMAP-CAP Australia
Colin McArthur, Dr
Role: STUDY_CHAIR
Medical Research Institute of New Zealand, Study Chair REMAP-CAP New Zealand
Marc Bonten, Prof
Role: STUDY_CHAIR
UMC Utrecht, Study Chair REMAP-CAP Europe
Lennie Derde, MD
Role: STUDY_CHAIR
UMC Utrecht, Coordinating Investigator REMAP-CAP Europe
John Marshall, Prof
Role: STUDY_CHAIR
Unity Health Toronto, Study Chair REMAP-CAP Canada
Derek Angus, Prof
Role: STUDY_CHAIR
University of Pittsburgh Medical Center, Study Chair REMAP-CAP USA
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Florida
Jacksonville, Florida, United States
Augusta University
Augusta, Georgia, United States
University of Illinois Health
Chicago, Illinois, United States
Tulane Medical Center
New Orleans, Louisiana, United States
University of Michigan
Ann Arbor, Michigan, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Wake Forest Baptist Health
Winston-Salem, North Carolina, United States
The Ohio State University Wexner Medical Center
Columbus, Ohio, United States
Oregon Health and Science University
Portland, Oregon, United States
University of Pittsburgh Medical Centre
Pittsburgh, Pennsylvania, United States
Brown University - Rhode Island Hospital
Providence, Rhode Island, United States
Canberra Hospital
Canberra, Australian Capital Territory, Australia
Bankstown-Lidcombe Hospital
Bankstown, New South Wales, Australia
Blacktown Hospital
Blacktown, New South Wales, Australia
Campbelltown Hospital
Campbelltown, New South Wales, Australia
Sutherland Hospital
Caringbah, New South Wales, Australia
Concord Hospital
Concord, New South Wales, Australia
Dubbo Base Hospital
Dubbo, New South Wales, Australia
Northern Beaches Hospital
Frenchs Forest, New South Wales, Australia
Nepean Hospital
Kingswood, New South Wales, Australia
St. George Hospital
Kogarah, New South Wales, Australia
Liverpool Hospital
Liverpool, New South Wales, Australia
John Hunter Hospital
Newcastle, New South Wales, Australia
Orange Health Service
Orange, New South Wales, Australia
St Vincent's Hospital Sydney
Sydney, New South Wales, Australia
Prince of Wales Hospital
Sydney, New South Wales, Australia
Royal Prince Alfred Hospital
Sydney, New South Wales, Australia
Royal North Shore Hospital
Sydney, New South Wales, Australia
Wollongong Hospital
Sydney, New South Wales, Australia
Wagga Wagga Base Hospital
Wagga Wagga, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Royal Darwin Hospital,
Darwin, Northern Territory, Australia
Sunshine Coast University Hospital
Birtinya, Queensland, Australia
The Prince Charles Hospital
Brisbane, Queensland, Australia
Mater Hospital Brisbane
Brisbane, Queensland, Australia
Princess Alexandra Hospital
Brisbane, Queensland, Australia
Caboolture Hospital
Caboolture, Queensland, Australia
Queen Elizabeth II Jubilee Hospital
Coopers Plains, Queensland, Australia
Logan Hospital
Logan City, Queensland, Australia
Redcliffe Hospital
Redcliffe, Queensland, Australia
Rockhampton Hospital
Rockhampton, Queensland, Australia
Gold Coast University Hospital
Southport, Queensland, Australia
Toowoomba Hospital
Toowoomba, Queensland, Australia
Townsville Hospital
Townsville, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
The Queen Elizabeth Hospital
Adelaide, South Australia, Australia
Lyell McEwin Hospital
Adelaide, South Australia, Australia
Flinders Medical Centre
Bedford Park, South Australia, Australia
Launceston Hospital
Launceston, Tasmania, Australia
Ballarat Base Hospital
Ballarat, Victoria, Australia
Bendigo Hospital
Bendigo, Victoria, Australia
Casey Hospital
Berwick, Victoria, Australia
Box Hill Hospital
Box Hill, Victoria, Australia
Monash Medical Centre
Clayton, Victoria, Australia
Dandenong Hospital
Dandenong, Victoria, Australia
Angliss Hospital
Ferntree Gully, Victoria, Australia
Footscray Hospital
Footscray, Victoria, Australia
University Hosptial Geelong
Geelong, Victoria, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Royal Melbourne Hospital
Melbourne, Victoria, Australia
St Vincent's Hospital Melbourne
Melbourne, Victoria, Australia
Maroondah Hospital
Ringwood East, Victoria, Australia
Sunshine Hospital
Sunshine, Victoria, Australia
Werribee Mercy Hospital
Werribee, Victoria, Australia
St John of God Hospital Midland
Midland, Western Australia, Australia
St John of God Hospital Murdoch
Murdoch, Western Australia, Australia
Royal Perth Hospital
Perth, Western Australia, Australia
Sir Charles Gairdner Hospital
Perth, Western Australia, Australia
Fiona Stanley Hospital
Perth, Western Australia, Australia
St John of God Subiaco
Subiaco, Western Australia, Australia
CHU de Charleroi - Hôpital Civil Marie Curie
Charleroi, , Belgium
Universitair Ziekenhuis Gent
Ghent, , Belgium
CHU Namur site Godinne
Namur, , Belgium
Foothills Medical Centre
Calgary, Alberta, Canada
Peter Lougheed Centre
Calgary, Alberta, Canada
Rockyview General Hospital
Calgary, Alberta, Canada
South Health Campus
Calgary, Alberta, Canada
Royal Alexandra Hospital, Alberta
Edmonton, Alberta, Canada
University of Alberta Hospital
Edmonton, Alberta, Canada
Surrey Memorial Hospital
Surrey, British Columbia, Canada
St Boniface General Hospital
Winnipeg, Manitoba, Canada
Health Sciences Centre Winnipeg
Winnipeg, Manitoba, Canada
Grace Hospital
Winnipeg, Manitoba, Canada
Dr. Everett Chalmers Regional Hospital
Fredericton, New Brunswick, Canada
The Moncton Hospital
Fredericton, New Brunswick, Canada
The Saint John General Hospital
Fredericton, New Brunswick, Canada
William Osler Health System
Brampton, Ontario, Canada
Brantford General Hospital
Brantford, Ontario, Canada
Hamilton general Hospital
Hamilton, Ontario, Canada
Juravinski Hospital
Hamilton, Ontario, Canada
St. Joseph's Healthcare Hamilton
Hamilton, Ontario, Canada
Kingston Health Sciences Centre
Kingston, Ontario, Canada
Grand River Hospital
Kitchener, Ontario, Canada
St Mary's General Hospital
Kitchener, Ontario, Canada
The Ottawa Hospital
Ottawa, Ontario, Canada
Niagara Health
St. Catharines, Ontario, Canada
Thunder Bay General Hospital
Thunder Bay, Ontario, Canada
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
St. Michael's Hospital Unity Health Toronto
Toronto, Ontario, Canada
Mount Sinai Hospital
Toronto, Ontario, Canada
Toronto General Hospital
Toronto, Ontario, Canada
Toronto Western Hospital
Toronto, Ontario, Canada
St Joseph's Health Centre
Toronto, Ontario, Canada
CIUSS Chaudieres-Appalaches (Levis)
Lévis, Quebec, Canada
Hospital Maisonneuve-Rosemont
Montreal, Quebec, Canada
Hôpital Fleury
Montreal, Quebec, Canada
Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, Canada
McGill University Health Centre
Montreal, Quebec, Canada
Hopital du Sacre-Coeur de Montreal
Montreal, Quebec, Canada
CHU de Québec - Université Laval
Québec, Quebec, Canada
IUCPQ-UL
Québec, Quebec, Canada
Centre Hospitalier de l'Université de Sherbrooke
Sherbrooke, Quebec, Canada
Regina General Hospital
Saskatoon, Saskatchewan, Canada
Universidad de La Sabana
Chía, Cundinamarca, Colombia
General County Hospital Požega
Požega, , Croatia
University Hospital Centre Zagreb
Zagreb, , Croatia
University Hospital for Infectious Diseases
Zagreb, , Croatia
Fakultní nemocnice Královské Vinohrady
Prague, , Czechia
Teplice Hospital
Teplice, , Czechia
Tartu University Hospital
Tartu, , Estonia
Helsinki University Hospital
Helsinki, , Finland
Tampere University Hospital
Tampere, , Finland
CH Argenteuil
Argenteuil, , France
Centre Hospitalier Henri Mondor d'Aurillac
Aurillac, , France
Beauvais General Hospital
Beauvais, , France
Hopital Nord Franche-Comte
Belfort, , France
Centre hospitalier Bethune Beuvry
Béthune, , France
Ambroise Pare Hospital
Boulogne-Billancourt, , France
CH de Dax
Dax, , France
Centre Hospitalier de Dieppe
Dieppe, , France
CHU Dijon Bourgogne
Dijon, , France
Hopital Simone Veil Eaubonne
Eaubonne, , France
Sud Essonne Hospital Etampes
Étampes, , France
Hospital Raymond Poincare
Garches, , France
CHD Vendee
La Roche-sur-Yon, , France
Centre Hospitalier Le Mans
Le Mans, , France
CHU Dupuytren
Limoges, , France
Centre Hospitalier de Melun
Melun, , France
Centre Hospitalier Layne - Mont-de-Marsan
Mont-de-Marsan, , France
Centre Hospitalier des Pays de Morlaix
Morlaix, , France
CHR d'Orleans
Orléans, , France
Lariboisiere Hospital
Paris, , France
Hopital Tenon
Paris, , France
Nouvel Hopital Civil Strasbourg
Strasbourg, , France
Hopital de Hautepierre Strasbourg
Strasbourg, , France
CHRU Tours Hopital Bretonneau
Tours, , France
Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie
Berlin, , Germany
Vivantes Klinikum Neukölln
Berlin, , Germany
Charite Universitätsmedizin Berlin
Berlin, , Germany
Vivantes Humboldt-Klinikum
Berlin, , Germany
University Hospital of Cologne
Cologne, , Germany
Carl-Thiem-Klinikum Cottbus
Cottbus, , Germany
Klinikum Dortmund
Dortmund, , Germany
Elisabeth Hospital Essen
Essen, , Germany
Universitätsklinikum Frankfurt
Frankfurt, , Germany
University Medical Center Hamburg-Eppendorf (UKE)
Hamburg, , Germany
Universitätsklinikum Jena
Jena, , Germany
University Hospital Leipzig
Leipzig, , Germany
Universitätsklinikum Leipzig
Leipzig, , Germany
Klinikum rechts der Isar der TU München
München, , Germany
Universitätsklinikum Münster
Münster, , Germany
Universitäts Klinikum Tübingen
Tübingen, , Germany
Universitätsklinikum Würzburg
Würzburg, , Germany
Jósa András County Hospital
Nyíregyháza, , Hungary
Almási Balogh Pál Kórház
Ózd, , Hungary
Apollo Main Hospital
Chennai, Tamil Nadu, India
Apollo First Med Hospital
Chennai, Tamil Nadu, India
Apollo Vanagaram Hospital
Chennai, Tamil Nadu, India
Apollo Speciality Hospital - OMR
Chennai, Tamil Nadu, India
Cork University Hospital
Cork, , Ireland
Beaumont Hospital
Dublin, , Ireland
St. Vincent's University Hospital
Dublin, , Ireland
University Hospital Galway
Galway, , Ireland
University Hospital Waterford
Waterford, , Ireland
Rambam Medical Center
Haifa, , Israel
Beilinson Hospital, Rabin Medical Center
Petah Tikva, , Israel
The Baruch Padeh Medical Center
Poria – Neve Oved, , Israel
AO Spedali Civili di Brescia
Brescia, , Italy
Humanitas Research Hospital
Milan, , Italy
Ca' Granda Ospedale Maggiore Policlinico
Milan, , Italy
IRCCS Ospedale San Raffaele
Milan, , Italy
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
Palermo, , Italy
Istituto Mediterraneo per i Trapianti e Terapie ad alta specializzazione
Palermo, , Italy
Arcispedale S. Maria Nuova
Reggio Emilia, , Italy
Ospedale Infermi di Rimini
Rimini, , Italy
St Marianna University School of Medicine
Kawasaki, Kanagawa, Japan
Yokohama City University Hospital
Yokohama, Kanagawa, Japan
St. Marianna University Yokohama City Seibu Hospital
Yokohama, Kanagawa, Japan
Saiseikai Kumamoto Hospital
Minami, Kumamoto, Japan
Osaka City General Hospital
Osaka, , Japan
Nerima Hikarigaoka Hospital
Tokyo, , Japan
Tokyo Metropolitan Bokutoh Hospital
Tokyo, , Japan
Itabashi Chuo Medical Center
Tokyo, , Japan
Tokyo bay Urayasu-Ichikawa Medical Center
Tokyo, , Japan
Wakayama Medical University
Wakayama, , Japan
Chitwan Medical College
Bharatpur, , Nepal
Grande International Hospital
Kathmandu, , Nepal
Hospital for Advanced Medicine and Surgery (HAMS)
Kathmandu, , Nepal
Nepal Mediciti
Kathmandu, , Nepal
Jeroen Bosch Ziekenhuis
's-Hertogenbosch, , Netherlands
ZGT Almelo
Almelo, , Netherlands
Meander Medisch Centrum
Amersfoort, , Netherlands
OLVG
Amsterdam, , Netherlands
Rijnstate Hospital
Arnhem, , Netherlands
Deventer Hospital
Deventer, , Netherlands
Ziekenhuis Gelderse Vallei
Ede, , Netherlands
Maxima Medisch Centrum Eindhoven
Eindhoven, , Netherlands
Martini Hospital Groningen
Groningen, , Netherlands
University Medical Center Groningen
Groningen, , Netherlands
Medisch Centrum Leeuwarden
Leeuwarden, , Netherlands
Leiden University Medical Center
Leiden, , Netherlands
Canisius Wilhelmina Ziekenhuis
Nijmegen, , Netherlands
Radboud University Medical Center
Nijmegen, , Netherlands
Laurentius Hospital
Roermond, , Netherlands
Maasstad Ziekenhuis
Rotterdam, , Netherlands
Hagaziekenhuis
The Hague, , Netherlands
Bernhoven Hospital
Uden, , Netherlands
University Medical Center Utrecht
Utrecht, , Netherlands
North Shore Hospital
Auckland, , New Zealand
CVICU, Auckland City Hospital
Auckland, , New Zealand
DCCM, Auckland City Hospital
Auckland, , New Zealand
Middlemore Hospital
Auckland, , New Zealand
Christchurch Hospital
Christchurch, , New Zealand
Waikato Hospital
Hamilton, , New Zealand
Taranaki Base Hospital
New Plymouth, , New Zealand
Rotorua Hospital
Rotorua, , New Zealand
Tauranga Hospital
Tauranga, , New Zealand
Wellington Regional Hospital
Wellington, , New Zealand
Whangarei Hospital
Whangarei, , New Zealand
Ziauddin University Hospital Clifton Campus
Karachi, Sindh, Pakistan
Abbasi Shaheed Hospital
Karachi, Sindh, Pakistan
National Institute of Cardiovascular Diseases, Karachi
Karachi, Sindh, Pakistan
South City Hospital, Karachi
Karachi, Sindh, Pakistan
Ziauddin University North Nazimabad Campus
Karachi, Sindh, Pakistan
Centro Hospitalar do Medio Tejo
Abrantes, , Portugal
Hospital Ocidental
Lisbon, , Portugal
Hospital Lusíadas Lisbon
Lisbon, , Portugal
Clinical Hospital of Infectious and Tropical Diseases "Dr. Victor Babes"
Bucharest, , Romania
King Abdulaziz Medical City
Riyadh, , Saudi Arabia
University Clinical Centre of Serbia
Belgrade, , Serbia
University Hospital Center Dr Dragiša Mišović
Belgrade, , Serbia
Clinical Centre of Niš
Niš, , Serbia
University Clinic of Respiratory and Allergic Diseases Golnik
Golnik, , Slovenia
University Medical Centre Maribor
Maribor, , Slovenia
Hospital del Mar
Barcelona, , Spain
Hospital Universitario de Jerez
Cadiz, , Spain
Reina Sofia University Hospital
Córdoba, , Spain
Ramon y Cajal University Hospital
Madrid, , Spain
Hospital Regional de Málaga
Málaga, , Spain
Hospital Universitario de Ourense
Ourense, , Spain
Hospital Marqués de Valdecilla
Santander, , Spain
Hospital Verge de la Cinta
Tortosa, , Spain
Doctor Peset University Hospital
Valencia, , Spain
Hospital La Fe
Valencia, , Spain
University Hospital Zürich
Zurich, , Switzerland
Basildon Hospital
Basildon, England, United Kingdom
Basingstoke and North Hampshire Hospital
Basingstoke, England, United Kingdom
Royal United Hospital, Bath
Bath, England, United Kingdom
Queen Elizabeth Hospital Birmingham
Birmingham, England, United Kingdom
Birmingham City Hospital
Birmingham, England, United Kingdom
Royal Blackburn Teaching Hospital
Blackburn, England, United Kingdom
Pilgrim Hospital ULHT
Boston, England, United Kingdom
Royal Bournemouth Hospital
Bournemouth, England, United Kingdom
Royal Sussex County Hospital
Brighton, England, United Kingdom
Southmead Hospital
Bristol, England, United Kingdom
Bristol Royal Infirmary
Bristol, England, United Kingdom
Queen's Hospital, Burton
Burton-on-Trent, England, United Kingdom
Royal Papworth Hospital
Cambridge, England, United Kingdom
Addenbrookes Hospital
Cambridge, England, United Kingdom
North Cumberland Infirmary
Carlisle, England, United Kingdom
St Peter's Hospital
Chertsey, England, United Kingdom
Countess of Chester Hospital
Chester, England, United Kingdom
Chesterfield Royal Hospital
Chesterfield, England, United Kingdom
Colchester Hospital
Colchester, England, United Kingdom
University Hospital Coventry
Coventry, England, United Kingdom
Darlington Memorial Hospital
Darlington, England, United Kingdom
Darent Valley Hospital
Dartford, England, United Kingdom
Russells Hall Hospital
Dudley, England, United Kingdom
Royal Devon and Exeter Hospital
Exeter, England, United Kingdom
Frimley Park Hospital
Frimley, England, United Kingdom
Queen Elizabeth Hospital Gateshead
Gateshead, England, United Kingdom
Medway Maritime Hospital
Gillingham, England, United Kingdom
James Paget University Hospital
Great Yarmouth, England, United Kingdom
Royal Surrey County Hospital
Guildford, England, United Kingdom
Northwick Park Hospital
Harrow, England, United Kingdom
Hereford County Hospital
Hereford, England, United Kingdom
Barnet Hospital
High Barnet, England, United Kingdom
Huddersfield Royal Infirmary
Huddersfield, England, United Kingdom
King George Hospital
Ilford, England, United Kingdom
Ipswich Hospital
Ipswich, England, United Kingdom
Kettering Hospital
Kettering, England, United Kingdom
Leeds General Infirmary
Leeds, England, United Kingdom
Leicester Royal Infirmary
Leicester, England, United Kingdom
Glenfield Hospital
Leicester, England, United Kingdom
Lincoln County Hospital
Lincoln, England, United Kingdom
Liverpool Heart and Chest Hospital
Liverpool, England, United Kingdom
Alder Hey Hospital
Liverpool, England, United Kingdom
Royal Liverpool University Hospital
Liverpool, England, United Kingdom
University Hospital Aintree
Liverpool, England, United Kingdom
Croydon University Hospital
London, England, United Kingdom
Royal London Hospital
London, England, United Kingdom
Whipps Cross Hospital
London, England, United Kingdom
Newham University Hospital
London, England, United Kingdom
St Bartholomew's Hospital
London, England, United Kingdom
North Middlesex University Hospital
London, England, United Kingdom
Royal Free Hospital
London, England, United Kingdom
St Thomas Hospital
London, England, United Kingdom
Guy's Hospital
London, England, United Kingdom
Queen Elizabeth Hospital, Woolwich
London, England, United Kingdom
King's College Hospital
London, England, United Kingdom
St George's University Hospital
London, England, United Kingdom
Royal Marsden Hospital
London, England, United Kingdom
Royal Brompton Hospital
London, England, United Kingdom
Hammersmith Hospital
London, England, United Kingdom
St Mary's Hospital
London, England, United Kingdom
Charing Cross Hospital
London, England, United Kingdom
Luton and Dunstable University Hospital
Luton, England, United Kingdom
Maidstone Hospital
Maidstone, England, United Kingdom
Manchester Royal Infirmary
Manchester, England, United Kingdom
The Christie Hospital
Manchester, England, United Kingdom
Wythenshawe Hospital
Manchester, England, United Kingdom
North Manchester General Hospital
Manchester, England, United Kingdom
Arrowe Park Hospital
Metropolitan Borough of Wirral, England, United Kingdom
The James Cook University Hospital
Middlesbrough, England, United Kingdom
Milton Keynes University Hospital
Milton Keynes, England, United Kingdom
Royal Victoria Infirmary, Newcastle
Newcastle, England, United Kingdom
Newcastle Freeman Hospital
Newcastle, England, United Kingdom
Northampton General Hospital
Northampton, England, United Kingdom
Norfolk and Norwich University Hospital
Norwich, England, United Kingdom
City Hospital Nottingham
Nottingham, England, United Kingdom
Queen's Medical Centre - Nottingham University Hospitals NHS Trust
Nottingham, England, United Kingdom
George Eliot Hospital
Nuneaton, England, United Kingdom
Royal Oldham Hospital
Oldham, England, United Kingdom
Princess Royal University Hospital
Orpington, England, United Kingdom
John Radcliffe Hospital
Oxford, England, United Kingdom
Derriford Hospital
Plymouth, England, United Kingdom
Poole Hospital NHS Foundation Trust
Poole, England, United Kingdom
Queen Alexandra Hospital
Portsmouth, England, United Kingdom
Whiston Hospital
Prescot, England, United Kingdom
Royal Preston Hospital
Preston, England, United Kingdom
Royal Berkshire Hospital
Reading, England, United Kingdom
Alexandra Hospital, Redditch
Redditch, England, United Kingdom
Queen's Hospital Romford
Romford, England, United Kingdom
Rotherham Hospital
Rotherham, England, United Kingdom
Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust
Royal Tunbridge Wells, England, United Kingdom
Salford Royal Hospital
Salford, England, United Kingdom
Salisbury District Hospital
Salisbury, England, United Kingdom
Royal Hallamshire Hospital
Sheffield, England, United Kingdom
Northern General Hospital
Sheffield, England, United Kingdom
Wexham Park Hospital
Slough, England, United Kingdom
South Tyneside District Hospital
South Shields, England, United Kingdom
Southampton General Hospital
Southampton, England, United Kingdom
Stepping Hill Hospital
Stockport, England, United Kingdom
University Hospital of North Tees
Stockton-on-Tees, England, United Kingdom
Royal Stoke University Hospital
Stoke-on-Trent, England, United Kingdom
Sunderland Royal Hospital
Sunderland, England, United Kingdom
King's Mill Hospital
Sutton in Ashfield, England, United Kingdom
Great Western Hospital
Swindon, England, United Kingdom
Western General Hospital
Swindon, England, United Kingdom
Musgrove Park Hospital
Taunton, England, United Kingdom
Torbay Hospital
Torquay, England, United Kingdom
Royal Cornwall Hospital
Truro, England, United Kingdom
Harefield Hospital
Uxbridge, England, United Kingdom
Watford General Hospital
Watford, England, United Kingdom
Southend Hospital
Westcliff-on-Sea, England, United Kingdom
West Cumberland Hospital
Whitehaven, England, United Kingdom
Royal Albert Edward Infirmary
Wigan, England, United Kingdom
Royal Hampshire County Hospital
Winchester, England, United Kingdom
New Cross Hospital Wolverhampton
Wolverhampton, England, United Kingdom
Worcestershire Royal Hospital
Worcester, England, United Kingdom
York Teaching Hospital
York, England, United Kingdom
Antrim Area Hospital
Antrim, Northern Ireland, United Kingdom
Royal Victoria Hospital Belfast
Belfast, Northern Ireland, United Kingdom
Mater Hospital
Belfast, Northern Ireland, United Kingdom
Belfast City Hospital
Belfast, Northern Ireland, United Kingdom
Altnagelvin Hospital
Londonderry, Northern Ireland, United Kingdom
Aberdeen Royal Infirmary
Aberdeen, Scotland, United Kingdom
Ninewells Hospital
Dundee, Scotland, United Kingdom
Royal Infirmary of Edinburgh
Edinburgh, Scotland, United Kingdom
Glasgow Royal Infirmary
Glasgow, Scotland, United Kingdom
Queen Elizabeth University Hospital, Glasgow
Glasgow, Scotland, United Kingdom
Royal Alexandra Hospital
Paisley, Scotland, United Kingdom
Neville Hall Hospital
Abergavenny, Wales, United Kingdom
Glan Clwyd Hospital
Bodelwyddan, Wales, United Kingdom
Princess of Wales Hospital
Bridgend, Wales, United Kingdom
Cardiff and Vale University Hospital Wales
Cardiff, Wales, United Kingdom
Glangwilli Hospital
Carmarthen, Wales, United Kingdom
Grange University Hospital
Cwmbran, Wales, United Kingdom
Royal Gwent Hospital
Newport, Wales, United Kingdom
Royal Glamorgan Hospital
Pont-y-clun, Wales, United Kingdom
Morriston Hospital
Swansea, Wales, United Kingdom
Wrexham Maelor Hospital
Wrexham, Wales, United Kingdom
Ulster Hospital
Belfast, , United Kingdom
Bristol Royal Childrens Hospital
Bristol, , United Kingdom
Fairfield General Hospital
Bury, , United Kingdom
Leighton Hospital
Crewe, , United Kingdom
Dorset County Hospital
Dorchester, , United Kingdom
Gloucester Royal Hospital
Gloucester, , United Kingdom
The Princess Royal Hospital Haywards Heath
Haywards Heath, , United Kingdom
St. James University Hospital
Leeds, , United Kingdom
Homerton Hospital
London, , United Kingdom
University College London Hospital
London, , United Kingdom
Chelsea and Westminster Hospital
London, , United Kingdom
Queen Elizabeth and Queen Mother Hospital
Margate, , United Kingdom
Newcastle Royal Victoria Infirmary (Paediatrics)
Newcastle upon Tyne, , United Kingdom
North Tyneside General Hospital
North Shields, , United Kingdom
Warwick Hospital
Warwick, , United Kingdom
Sandwell General Hospital
West Bromwich, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Hadi Hatoum, MD
Role: primary
Jose Vazquez, MD
Role: primary
Jeffrey Jacobson, MD
Role: primary
Joshua Denson, MD
Role: primary
Robert Hyzy, MD
Role: primary
Stephen Pastores, MD
Role: primary
Ashish Khanna, MD
Role: primary
Matthew Exline, MD
Role: primary
Akram Khankhana, MD
Role: primary
Stephanie Mongomery
Role: primary
Mitchell Levy, MD
Role: primary
Patrick Biston, MD
Role: primary
Pieter Depuydt, Prof.
Role: primary
Pierre Bulpa, MD
Role: primary
Demetrios Kutsogiannis, MD
Role: primary
Wendy Sligl, MD
Role: primary
Anish Mitra, MD
Role: primary
Ryan Zarychanski, MD
Role: primary
Ryan Zarychanski, MD
Role: primary
Gloria Vazquez-Grande, MD
Role: primary
Zeeshan Aslam, MD
Role: primary
Daniel Smyth, MD
Role: primary
Stephen Robinson, MD
Role: primary
Alexandra Binnie, MD
Role: primary
Brenda Reeve, MD
Role: primary
Alison Fox-Robichaud, MD
Role: primary
Bram Rochwerg, MD
Role: primary
Deborah Cook, MD
Role: primary
Theresa Liu, MD
Role: primary
Rebecca Kruisselbrink, MD
Role: primary
Lauralyn McIntyre, MD
Role: primary
Jennifer Tsang, MD
Role: primary
Rob Fowler, MD
Role: primary
John Marshall, MD
Role: primary
Sangeeta Mehta, MD
Role: primary
Lorenzo del Sorbo, MD
Role: primary
Elizabeth Wilcox, MD
Role: primary
Patrick Archambault, MD
Role: primary
Thomas Hemmerling, MD
Role: primary
Michael Chasse, MD
Role: primary
Kosar Khwaja, MD
Role: primary
Martin Albert, MD
Role: primary
Alexis Turgeon, MD
Role: primary
Francois Lellouche, MD
Role: primary
Francois Lamontagne, MD
Role: primary
Eric Sy, MD
Role: primary
Zdravko Andrić, MD
Role: primary
Ana Vujaklija Brajković, MD
Role: primary
František Duška, MD
Role: primary
Christophe Vinsonneau, MD
Role: primary
Antoine Vieillard Baron, MD
Role: primary
Adrien Auvet, MD
Role: primary
Peierre-Louis Declercq, MD
Role: primary
Jean-Pierre Quenot, MD
Role: primary
Djillali Annane, MD
Role: primary
Gwenael Colin, MD
Role: primary
Christophe Guitton, MD
Role: primary
Francois Bruno, MD
Role: primary
Arnaud Sement, MD
Role: primary
Pierre Yves Egreteau, MD
Role: primary
Ferhat Meziani, MD
Role: primary
Emmanuelle Mercier, MD
Role: primary
Meghena Mathew, MD
Role: primary
Deva Jayakumar, MD
Role: primary
Ger Curley, Prof.
Role: primary
Alistair Nichol, Prof.
Role: primary
John Laffey, M.D.
Role: primary
Simone Piva, MD
Role: primary
Maurizio Cecconi, MD
Role: primary
Francesco Blasi, MD
Role: primary
Giovanni Landoni, MD
Role: primary
Andrea Cortegiani, MD
Role: primary
Gennaro Martucci, MD
Role: primary
Elena Mantovani, MD
Role: primary
Jonathan Montomoli, MD
Role: primary
Basanta Gauli, MD
Role: primary
Sushil Khanal, MD
Role: primary
Hem Paneru, MD
Role: primary
Diptesh Aryal, MD
Role: primary
Koen Simons, M.D.
Role: primary
Bastiaan Wittekamp, MD
Role: primary
Laura van Gulik, M.D.
Role: primary
Robert-Jan Hassing, MD
Role: primary
Evert De Jonge, Prof.
Role: primary
Oscar Hoiting, M.D.
Role: primary
Frank van de Veerdonk, Prof.
Role: primary
Corstiaan den Uil, MD
Role: primary
Thomas Ottens, MD
Role: primary
Marc Bonten, Prof.
Role: primary
Lennie Derde, MD
Role: backup
Robert Everitt, MD
Role: primary
Shay McGuinness, MD
Role: primary
Colin McArthur, MD
Role: primary
Tony Williams, MD
Role: primary
Jay Ritzema-Carter, MD
Role: primary
Robert Martynoga, MD
Role: primary
Jonathan Albrett, MD
Role: primary
Ulrike Buehner, MD
Role: primary
Troy Browne, MD
Role: primary
Paul Young, MD
Role: primary
Ralph Fuchs, MD
Role: primary
Madiha Hashmi, MD
Role: primary
Aneela Kidwai, MD
Role: primary
Nawal Salahuddin, MD
Role: primary
Nasir Khoso, MD
Role: primary
Quratul Ain, MD
Role: primary
Nuno Catorze, M.D.
Role: primary
Yaseen Arabi, MD
Role: primary
Tanja Pejčić, MD
Role: primary
Andre Markota, MD
Role: primary
Rosana Munoz-Bermúdez, M.D.
Role: primary
Ángel Estella, MD
Role: primary
Eduardo Aguilar Alonso, M.D.
Role: primary
Cruz Soriano, MD
Role: primary
Manuel Herrera Gutiérrez, MD
Role: primary
Pablo Vidal, MD
Role: primary
Borja Suberviola, MD
Role: primary
Ferran Roche Campo, MD
Role: primary
Rafael Zaragoza, MD
Role: primary
Paula Ramírez, MD
Role: primary
Irena Grecu, MD
Role: primary
Dhruv Parekh
Role: primary
Jonathan Hulme
Role: primary
Srikanth Chukkambotla, MD
Role: primary
Euan Mackay
Role: primary
Mohamed Ramali
Role: primary
Ben Creagh-Brown
Role: primary
Charlotte Small
Role: primary
Dhinesh Sundaran
Role: primary
Marlies Ostermann
Role: primary
Phillip Hopkins
Role: primary
Susannah Leaver
Role: primary
Stephen Brett
Role: primary
Anthony Gordon
Role: primary
David Antcliffe
Role: primary
David Golden, MD
Role: primary
Craig Denmade, MD
Role: primary
Jeremy Henning, MD
Role: primary
Richard Stewart, MD
Role: primary
Daniel Harvey, MD
Role: primary
Daniel Harvey, MD
Role: primary
Redmond Tully, MD
Role: primary
Nikitas Nikitas, MD
Role: primary
Henrik Reschreiter, MD
Role: primary
David Pogson, MD
Role: primary
Andrew Walden, MD
Role: primary
Anil Hormis, MD
Role: primary
David Golden, MD
Role: primary
Paul Dark, MD
Role: primary
Phil Donnison, MD
Role: primary
Gary Mills, MD
Role: primary
Gary Mills, MD
Role: primary
Alistair Roy, MD
Role: primary
Ahilanandan Dushianthan, MD
Role: primary
Hywel Garrard, MD
Role: primary
Farooq Brohi, MD
Role: primary
Ramprasad Matsa, MD
Role: primary
Alistair Roy, MD
Role: primary
Sandaruwan Herath, MD
Role: primary
Jonathan Rhodes, MD
Role: primary
Richard Innes, MD
Role: primary
Adam Revill, MD
Role: primary
Michael Spivey, MD
Role: primary
Valarie Page, MD
Role: primary
Irina Grecu, MD
Role: primary
Joseph Carter, MD
Role: primary
Paul Johnston, MD
Role: primary
Michael McGinlay, MD
Role: primary
Michael McGinlay, MD
Role: primary
Michael McGinlay, MD
Role: primary
Adrian Donnelly, MD
Role: primary
James Chambers, MD
Role: primary
Thomas Craven, MD
Role: primary
Kathryn Puxty, MD
Role: primary
Malcolm Sim, MD
Role: primary
Kevin Rooney, MD
Role: primary
David Southern, MD
Role: primary
Christopher Murray, MD
Role: primary
Jolanta Bernatoniene, MD
Role: primary
Andrew Claxton, MD
Role: primary
Richard Lowsby, MD
Role: primary
E Paramasivam, MD
Role: primary
Michael Marks, MD
Role: primary
Roger Davies, MD
Role: primary
Marieke Emonts, MD
Role: primary
Jonathan Hulme, MD
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Derde L, Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, Annane D, Beane A, Beasley R, Bonten MJM, Bradbury CA, Brunkhorst FM, Buzgau A, Buxton M, Cheng AC, Cooper N, Cove M, Cremer OL, Detry MA, Duffy EJ, Estcourt LJ, Fitzgerald M, Galea J, Goossens H, Haniffa R, Hills TE, Huang DT, Ichihara N, King A, Lamontagne F, Lawler PR, Leavis HL, Lewis RJ, Litton E, Marshall JC, Mayr FB, McAuley DF, McGlothlin A, McGuinness SP, McVerry BJ, Morpeth SC, Murthy S, Netea MG, Ogungbenro K, Orr K, Parke RL, Parker JC, Patanwala AE, Pettila V, Reyes LF, Saito H, Santos MS, Saunders CT, Seymour CW, Shankar-Hari M, Sligl WI, Turgeon AF, Turner AM, Tong SYC, Vaara S, Youngstein T, Zarychanski R, Green C, Higgins AM, McArthur CJ, Berry LR, Lorenzi E, Berry S, Webb SA, Angus DC, van de Veerdonk FL. Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19: a randomised, controlled, open-label, adaptive platform trial. Thorax. 2025 Jul 15;80(8):530-539. doi: 10.1136/thorax-2024-222488.
REMAP-CAP Investigators; Angus DC. Effect of hydrocortisone on mortality in patients with severe community-acquired pneumonia : The REMAP-CAP Corticosteroid Domain Randomized Clinical Trial. Intensive Care Med. 2025 Apr;51(4):665-680. doi: 10.1007/s00134-025-07861-w. Epub 2025 Apr 22.
REMAP-CAP Investigators; Hills TE, Lorenzi E, Berry LR, Shyamsundar M, Al-Beidh F, Annane D, Arabi Y, Aryal D, Au C, Beane A, Bhimani Z, Bonten M, Bradbury CA, Brunkhorst FM, Burrell A, Buxton M, Calfee CS, Cecconi M, Cheng AC, Cove ME, Detry MA, Estcourt LJ, Fitzgerald M, Goligher EC, Goossens H, Green C, Haniffa R, Harrison DA, Hashmi M, Higgins AM, Horvat C, Huang DT, Ichihara N, Jayakumar D, Kruger PS, Lamontagne F, Lampro L, Lawler PR, Marshall JC, Mason AJ, McGlothlin A, McGuinness S, McQuilten ZK, McVerry BJ, Mouncey PR, Murthy S, Neal MD, Nichol AD, O'Kane CM, Parke RL, Parker JC, Rabindrarajan E, Reyes LF, Rowan KM, Saito H, Santos M, Saunders CT, Seymour CW, Shankar-Hari M, Sinha P, Thompson BT, Turgeon AF, Turner AM, van de Veerdonk F, Weis S, Young IS, Zarychanski R, Lewis RJ, McArthur CJ, Angus DC, Berry SM, Derde LPG, Webb SA, Gordon AC, McAuley DF. Simvastatin in Critically Ill Patients with Covid-19. N Engl J Med. 2023 Dec 21;389(25):2341-2354. doi: 10.1056/NEJMoa2309995. Epub 2023 Oct 25.
LOVIT-COVID Investigators, on behalf of the Canadian Critical Care Trials Group, and the REMAP-CAP Investigators; Adhikari NKJ, Hashmi M, Tirupakuzhi Vijayaraghavan BK, Haniffa R, Beane A, Webb SA, Angus DC, Gordon AC, Cook DJ, Guyatt GH, Berry LR, Lorenzi E, Mouncey PR, Au C, Pinto R, Menard J, Sprague S, Masse MH, Huang DT, Heyland DK, Nichol AD, McArthur CJ, de Man A, Al-Beidh F, Annane D, Anstey M, Arabi YM, Battista MC, Berry S, Bhimani Z, Bonten MJM, Bradbury CA, Brant EB, Brunkhorst FM, Burrell A, Buxton M, Cecconi M, Cheng AC, Cohen D, Cove ME, Day AG, Derde LPG, Detry MA, Estcourt LJ, Fagbodun EO, Fitzgerald M, Goossens H, Green C, Higgins AM, Hills TE, Horvat C, Ichihara N, Jayakumar D, Kanji S, Khoso MN, Lawler PR, Lewis RJ, Litton E, Marshall JC, McAuley DF, McGlothlin A, McGuinness SP, McQuilten ZK, McVerry BJ, Murthy S, Parke RL, Parker JC, Reyes LF, Rowan KM, Saito H, Salahuddin N, Santos MS, Saunders CT, Seymour CW, Shankar-Hari M, Tolppa T, Trapani T, Turgeon AF, Turner AM, Udy AA, van de Veerdonk FL, Zarychanski R, Lamontagne F. Intravenous Vitamin C for Patients Hospitalized With COVID-19: Two Harmonized Randomized Clinical Trials. JAMA. 2023 Nov 14;330(18):1745-1759. doi: 10.1001/jama.2023.21407.
Fischer AL, Messer S, Riera R, Martimbianco ALC, Stegemann M, Estcourt LJ, Weibel S, Monsef I, Andreas M, Pacheco RL, Skoetz N. Antiplatelet agents for the treatment of adults with COVID-19. Cochrane Database Syst Rev. 2023 Jul 25;7(7):CD015078. doi: 10.1002/14651858.CD015078.
Writing Committee for the REMAP-CAP Investigators; Lawler PR, Derde LPG, van de Veerdonk FL, McVerry BJ, Huang DT, Berry LR, Lorenzi E, van Kimmenade R, Gommans F, Vaduganathan M, Leaf DE, Baron RM, Kim EY, Frankfurter C, Epelman S, Kwan Y, Grieve R, O'Neill S, Sadique Z, Puskarich M, Marshall JC, Higgins AM, Mouncey PR, Rowan KM, Al-Beidh F, Annane D, Arabi YM, Au C, Beane A, van Bentum-Puijk W, Bonten MJM, Bradbury CA, Brunkhorst FM, Burrell A, Buzgau A, Buxton M, Cecconi M, Cheng AC, Cove M, Detry MA, Estcourt LJ, Ezekowitz J, Fitzgerald M, Gattas D, Godoy LC, Goossens H, Haniffa R, Harrison DA, Hills T, Horvat CM, Ichihara N, Lamontagne F, Linstrum KM, McAuley DF, McGlothlin A, McGuinness SP, McQuilten Z, Murthy S, Nichol AD, Owen DRJ, Parke RL, Parker JC, Pollock KM, Reyes LF, Saito H, Santos MS, Saunders CT, Seymour CW, Shankar-Hari M, Singh V, Turgeon AF, Turner AM, Zarychanski R, Green C, Lewis RJ, Angus DC, Berry S, Gordon AC, McArthur CJ, Webb SA. Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial. JAMA. 2023 Apr 11;329(14):1183-1196. doi: 10.1001/jama.2023.4480.
Nurmi V, Knight C, Estcourt L, Hepojoki J, Lamikanra AA, Tsang HP, Roberts DJ, Polack FP, Simmonds P, Hedman K, Alvarez-Paggi D, Harvala H. The Relationship Between SARS-CoV-2 Neutralizing Antibody Titers and Avidity in Plasma Collected From Convalescent Nonvaccinated and Vaccinated Blood Donors. J Infect Dis. 2023 Aug 11;228(3):245-250. doi: 10.1093/infdis/jiad070.
Goligher EC, Lawler PR, Jensen TP, Talisa V, Berry LR, Lorenzi E, McVerry BJ, Chang CH, Leifer E, Bradbury C, Berger J, Hunt BJ, Castellucci LA, Kornblith LZ, Gordon AC, McArthur C, Webb S, Hochman J, Neal MD, Zarychanski R, Berry S, Angus DC; REMAP-CAP, ATTACC, and ACTIV-4a Investigators. Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19. JAMA. 2023 Apr 4;329(13):1066-1077. doi: 10.1001/jama.2023.3651.
REMAP-CAP Writing Committee for the REMAP-CAP Investigators; Bradbury CA, Lawler PR, Stanworth SJ, McVerry BJ, McQuilten Z, Higgins AM, Mouncey PR, Al-Beidh F, Rowan KM, Berry LR, Lorenzi E, Zarychanski R, Arabi YM, Annane D, Beane A, van Bentum-Puijk W, Bhimani Z, Bihari S, Bonten MJM, Brunkhorst FM, Buzgau A, Buxton M, Carrier M, Cheng AC, Cove M, Detry MA, Estcourt LJ, Fitzgerald M, Girard TD, Goligher EC, Goossens H, Haniffa R, Hills T, Huang DT, Horvat CM, Hunt BJ, Ichihara N, Lamontagne F, Leavis HL, Linstrum KM, Litton E, Marshall JC, McAuley DF, McGlothlin A, McGuinness SP, Middeldorp S, Montgomery SK, Morpeth SC, Murthy S, Neal MD, Nichol AD, Parke RL, Parker JC, Reyes LF, Saito H, Santos MS, Saunders CT, Serpa-Neto A, Seymour CW, Shankar-Hari M, Singh V, Tolppa T, Turgeon AF, Turner AM, van de Veerdonk FL, Green C, Lewis RJ, Angus DC, McArthur CJ, Berry S, Derde LPG, Webb SA, Gordon AC. Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2022 Apr 5;327(13):1247-1259. doi: 10.1001/jama.2022.2910.
Writing Committee for the REMAP-CAP Investigators; Estcourt LJ, Turgeon AF, McQuilten ZK, McVerry BJ, Al-Beidh F, Annane D, Arabi YM, Arnold DM, Beane A, Begin P, van Bentum-Puijk W, Berry LR, Bhimani Z, Birchall JE, Bonten MJM, Bradbury CA, Brunkhorst FM, Buxton M, Callum JL, Chasse M, Cheng AC, Cove ME, Daly J, Derde L, Detry MA, De Jong M, Evans A, Fergusson DA, Fish M, Fitzgerald M, Foley C, Goossens H, Gordon AC, Gosbell IB, Green C, Haniffa R, Harvala H, Higgins AM, Hills TE, Hoad VC, Horvat C, Huang DT, Hudson CL, Ichihara N, Laing E, Lamikanra AA, Lamontagne F, Lawler PR, Linstrum K, Litton E, Lorenzi E, MacLennan S, Marshall J, McAuley DF, McDyer JF, McGlothlin A, McGuinness S, Miflin G, Montgomery S, Mouncey PR, Murthy S, Nichol A, Parke R, Parker JC, Priddee N, Purcell DFJ, Reyes LF, Richardson P, Robitaille N, Rowan KM, Rynne J, Saito H, Santos M, Saunders CT, Serpa Neto A, Seymour CW, Silversides JA, Tinmouth AA, Triulzi DJ, Turner AM, van de Veerdonk F, Walsh TS, Wood EM, Berry S, Lewis RJ, Menon DK, McArthur C, Zarychanski R, Angus DC, Webb SA, Roberts DJ, Shankar-Hari M. Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2021 Nov 2;326(17):1690-1702. doi: 10.1001/jama.2021.18178.
Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.
REMAP-CAP Investigators; ACTIV-4a Investigators; ATTACC Investigators; Goligher EC, Bradbury CA, McVerry BJ, Lawler PR, Berger JS, Gong MN, Carrier M, Reynolds HR, Kumar A, Turgeon AF, Kornblith LZ, Kahn SR, Marshall JC, Kim KS, Houston BL, Derde LPG, Cushman M, Tritschler T, Angus DC, Godoy LC, McQuilten Z, Kirwan BA, Farkouh ME, Brooks MM, Lewis RJ, Berry LR, Lorenzi E, Gordon AC, Ahuja T, Al-Beidh F, Annane D, Arabi YM, Aryal D, Baumann Kreuziger L, Beane A, Bhimani Z, Bihari S, Billett HH, Bond L, Bonten M, Brunkhorst F, Buxton M, Buzgau A, Castellucci LA, Chekuri S, Chen JT, Cheng AC, Chkhikvadze T, Coiffard B, Contreras A, Costantini TW, de Brouwer S, Detry MA, Duggal A, Dzavik V, Effron MB, Eng HF, Escobedo J, Estcourt LJ, Everett BM, Fergusson DA, Fitzgerald M, Fowler RA, Froess JD, Fu Z, Galanaud JP, Galen BT, Gandotra S, Girard TD, Goodman AL, Goossens H, Green C, Greenstein YY, Gross PL, Haniffa R, Hegde SM, Hendrickson CM, Higgins AM, Hindenburg AA, Hope AA, Horowitz JM, Horvat CM, Huang DT, Hudock K, Hunt BJ, Husain M, Hyzy RC, Jacobson JR, Jayakumar D, Keller NM, Khan A, Kim Y, Kindzelski A, King AJ, Knudson MM, Kornblith AE, Kutcher ME, Laffan MA, Lamontagne F, Le Gal G, Leeper CM, Leifer ES, Lim G, Gallego Lima F, Linstrum K, Litton E, Lopez-Sendon J, Lother SA, Marten N, Saud Marinez A, Martinez M, Mateos Garcia E, Mavromichalis S, McAuley DF, McDonald EG, McGlothlin A, McGuinness SP, Middeldorp S, Montgomery SK, Mouncey PR, Murthy S, Nair GB, Nair R, Nichol AD, Nicolau JC, Nunez-Garcia B, Park JJ, Park PK, Parke RL, Parker JC, Parnia S, Paul JD, Pompilio M, Quigley JG, Rosenson RS, Rost NS, Rowan K, Santos FO, Santos M, Santos MO, Satterwhite L, Saunders CT, Schreiber J, Schutgens REG, Seymour CW, Siegal DM, Silva DG Jr, Singhal AB, Slutsky AS, Solvason D, Stanworth SJ, Turner AM, van Bentum-Puijk W, van de Veerdonk FL, van Diepen S, Vazquez-Grande G, Wahid L, Wareham V, Widmer RJ, Wilson JG, Yuriditsky E, Zhong Y, Berry SM, McArthur CJ, Neal MD, Hochman JS, Webb SA, Zarychanski R. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. N Engl J Med. 2021 Aug 26;385(9):777-789. doi: 10.1056/NEJMoa2103417. Epub 2021 Aug 4.
ATTACC Investigators; ACTIV-4a Investigators; REMAP-CAP Investigators; Lawler PR, Goligher EC, Berger JS, Neal MD, McVerry BJ, Nicolau JC, Gong MN, Carrier M, Rosenson RS, Reynolds HR, Turgeon AF, Escobedo J, Huang DT, Bradbury CA, Houston BL, Kornblith LZ, Kumar A, Kahn SR, Cushman M, McQuilten Z, Slutsky AS, Kim KS, Gordon AC, Kirwan BA, Brooks MM, Higgins AM, Lewis RJ, Lorenzi E, Berry SM, Berry LR, Aday AW, Al-Beidh F, Annane D, Arabi YM, Aryal D, Baumann Kreuziger L, Beane A, Bhimani Z, Bihari S, Billett HH, Bond L, Bonten M, Brunkhorst F, Buxton M, Buzgau A, Castellucci LA, Chekuri S, Chen JT, Cheng AC, Chkhikvadze T, Coiffard B, Costantini TW, de Brouwer S, Derde LPG, Detry MA, Duggal A, Dzavik V, Effron MB, Estcourt LJ, Everett BM, Fergusson DA, Fitzgerald M, Fowler RA, Galanaud JP, Galen BT, Gandotra S, Garcia-Madrona S, Girard TD, Godoy LC, Goodman AL, Goossens H, Green C, Greenstein YY, Gross PL, Hamburg NM, Haniffa R, Hanna G, Hanna N, Hegde SM, Hendrickson CM, Hite RD, Hindenburg AA, Hope AA, Horowitz JM, Horvat CM, Hudock K, Hunt BJ, Husain M, Hyzy RC, Iyer VN, Jacobson JR, Jayakumar D, Keller NM, Khan A, Kim Y, Kindzelski AL, King AJ, Knudson MM, Kornblith AE, Krishnan V, Kutcher ME, Laffan MA, Lamontagne F, Le Gal G, Leeper CM, Leifer ES, Lim G, Lima FG, Linstrum K, Litton E, Lopez-Sendon J, Lopez-Sendon Moreno JL, Lother SA, Malhotra S, Marcos M, Saud Marinez A, Marshall JC, Marten N, Matthay MA, McAuley DF, McDonald EG, McGlothlin A, McGuinness SP, Middeldorp S, Montgomery SK, Moore SC, Morillo Guerrero R, Mouncey PR, Murthy S, Nair GB, Nair R, Nichol AD, Nunez-Garcia B, Pandey A, Park PK, Parke RL, Parker JC, Parnia S, Paul JD, Perez Gonzalez YS, Pompilio M, Prekker ME, Quigley JG, Rost NS, Rowan K, Santos FO, Santos M, Olombrada Santos M, Satterwhite L, Saunders CT, Schutgens REG, Seymour CW, Siegal DM, Silva DG Jr, Shankar-Hari M, Sheehan JP, Singhal AB, Solvason D, Stanworth SJ, Tritschler T, Turner AM, van Bentum-Puijk W, van de Veerdonk FL, van Diepen S, Vazquez-Grande G, Wahid L, Wareham V, Wells BJ, Widmer RJ, Wilson JG, Yuriditsky E, Zampieri FG, Angus DC, McArthur CJ, Webb SA, Farkouh ME, Hochman JS, Zarychanski R. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N Engl J Med. 2021 Aug 26;385(9):790-802. doi: 10.1056/NEJMoa2105911. Epub 2021 Aug 4.
Arabi YM, Gordon AC, Derde LPG, Nichol AD, Murthy S, Beidh FA, Annane D, Swaidan LA, Beane A, Beasley R, Berry LR, Bhimani Z, Bonten MJM, Bradbury CA, Brunkhorst FM, Buxton M, Buzgau A, Cheng A, De Jong M, Detry MA, Duffy EJ, Estcourt LJ, Fitzgerald M, Fowler R, Girard TD, Goligher EC, Goossens H, Haniffa R, Higgins AM, Hills TE, Horvat CM, Huang DT, King AJ, Lamontagne F, Lawler PR, Lewis R, Linstrum K, Litton E, Lorenzi E, Malakouti S, McAuley DF, McGlothlin A, Mcguinness S, McVerry BJ, Montgomery SK, Morpeth SC, Mouncey PR, Orr K, Parke R, Parker JC, Patanwala AE, Rowan KM, Santos MS, Saunders CT, Seymour CW, Shankar-Hari M, Tong SYC, Turgeon AF, Turner AM, Van de Veerdonk FL, Zarychanski R, Green C, Berry S, Marshall JC, McArthur C, Angus DC, Webb SA; REMAP-CAP Investigators. Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. Intensive Care Med. 2021 Aug;47(8):867-886. doi: 10.1007/s00134-021-06448-5. Epub 2021 Jul 12.
REMAP-CAP Investigators; Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, Annane D, Beane A, van Bentum-Puijk W, Berry LR, Bhimani Z, Bonten MJM, Bradbury CA, Brunkhorst FM, Buzgau A, Cheng AC, Detry MA, Duffy EJ, Estcourt LJ, Fitzgerald M, Goossens H, Haniffa R, Higgins AM, Hills TE, Horvat CM, Lamontagne F, Lawler PR, Leavis HL, Linstrum KM, Litton E, Lorenzi E, Marshall JC, Mayr FB, McAuley DF, McGlothlin A, McGuinness SP, McVerry BJ, Montgomery SK, Morpeth SC, Murthy S, Orr K, Parke RL, Parker JC, Patanwala AE, Pettila V, Rademaker E, Santos MS, Saunders CT, Seymour CW, Shankar-Hari M, Sligl WI, Turgeon AF, Turner AM, van de Veerdonk FL, Zarychanski R, Green C, Lewis RJ, Angus DC, McArthur CJ, Berry S, Webb SA, Derde LPG. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021 Apr 22;384(16):1491-1502. doi: 10.1056/NEJMoa2100433. Epub 2021 Feb 25.
UPMC REMAP-COVID Group, on behalf of the REMAP-CAP Investigators. Implementation of the Randomized Embedded Multifactorial Adaptive Platform for COVID-19 (REMAP-COVID) trial in a US health system-lessons learned and recommendations. Trials. 2021 Jan 28;22(1):100. doi: 10.1186/s13063-020-04997-6.
Tume LN, Menzies JC, Ray S, Scholefield BR; UK Paediatric Intensive Care Society Study Group. Research Priorities for U.K. Pediatric Critical Care in 2019: Healthcare Professionals' and Parents' Perspectives. Pediatr Crit Care Med. 2021 May 1;22(5):e294-e301. doi: 10.1097/PCC.0000000000002647.
Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, Beane A, van Bentum-Puijk W, Berry L, Bhimani Z, Bonten M, Bradbury C, Brunkhorst F, Buxton M, Buzgau A, Cheng AC, de Jong M, Detry M, Estcourt L, Fitzgerald M, Goossens H, Green C, Haniffa R, Higgins AM, Horvat C, Hullegie SJ, Kruger P, Lamontagne F, Lawler PR, Linstrum K, Litton E, Lorenzi E, Marshall J, McAuley D, McGlothin A, McGuinness S, McVerry B, Montgomery S, Mouncey P, Murthy S, Nichol A, Parke R, Parker J, Rowan K, Sanil A, Santos M, Saunders C, Seymour C, Turner A, van de Veerdonk F, Venkatesh B, Zarychanski R, Berry S, Lewis RJ, McArthur C, Webb SA, Gordon AC; Writing Committee for the REMAP-CAP Investigators; Al-Beidh F, Angus D, Annane D, Arabi Y, van Bentum-Puijk W, Berry S, Beane A, Bhimani Z, Bonten M, Bradbury C, Brunkhorst F, Buxton M, Cheng A, De Jong M, Derde L, Estcourt L, Goossens H, Gordon A, Green C, Haniffa R, Lamontagne F, Lawler P, Litton E, Marshall J, McArthur C, McAuley D, McGuinness S, McVerry B, Montgomery S, Mouncey P, Murthy S, Nichol A, Parke R, Rowan K, Seymour C, Turner A, van de Veerdonk F, Webb S, Zarychanski R, Campbell L, Forbes A, Gattas D, Heritier S, Higgins L, Kruger P, Peake S, Presneill J, Seppelt I, Trapani T, Young P, Bagshaw S, Daneman N, Ferguson N, Misak C, Santos M, Hullegie S, Pletz M, Rohde G, Rowan K, Alexander B, Basile K, Girard T, Horvat C, Huang D, Linstrum K, Vates J, Beasley R, Fowler R, McGloughlin S, Morpeth S, Paterson D, Venkatesh B, Uyeki T, Baillie K, Duffy E, Fowler R, Hills T, Orr K, Patanwala A, Tong S, Netea M, Bihari S, Carrier M, Fergusson D, Goligher E, Haidar G, Hunt B, Kumar A, Laffan M, Lawless P, Lother S, McCallum P, Middeldopr S, McQuilten Z, Neal M, Pasi J, Schutgens R, Stanworth S, Turgeon A, Weissman A, Adhikari N, Anstey M, Brant E, de Man A, Lamonagne F, Masse MH, Udy A, Arnold D, Begin P, Charlewood R, Chasse M, Coyne M, Cooper J, Daly J, Gosbell I, Harvala-Simmonds H, Hills T, MacLennan S, Menon D, McDyer J, Pridee N, Roberts D, Shankar-Hari M, Thomas H, Tinmouth A, Triulzi D, Walsh T, Wood E, Calfee C, O'Kane C, Shyamsundar M, Sinha P, Thompson T, Young I, Bihari S, Hodgson C, Laffey J, McAuley D, Orford N, Neto A, Detry M, Fitzgerald M, Lewis R, McGlothlin A, Sanil A, Saunders C, Berry L, Lorenzi E, Miller E, Singh V, Zammit C, van Bentum Puijk W, Bouwman W, Mangindaan Y, Parker L, Peters S, Rietveld I, Raymakers K, Ganpat R, Brillinger N, Markgraf R, Ainscough K, Brickell K, Anjum A, Lane JB, Richards-Belle A, Saull M, Wiley D, Bion J, Connor J, Gates S, Manax V, van der Poll T, Reynolds J, van Beurden M, Effelaar E, Schotsman J, Boyd C, Harland C, Shearer A, Wren J, Clermont G, Garrard W, Kalchthaler K, King A, Ricketts D, Malakoutis S, Marroquin O, Music E, Quinn K, Cate H, Pearson K, Collins J, Hanson J, Williams P, Jackson S, Asghar A, Dyas S, Sutu M, Murphy S, Williamson D, Mguni N, Potter A, Porter D, Goodwin J, Rook C, Harrison S, Williams H, Campbell H, Lomme K, Williamson J, Sheffield J, van't Hoff W, McCracken P, Young M, Board J, Mart E, Knott C, Smith J, Boschert C, Affleck J, Ramanan M, D'Souza R, Pateman K, Shakih A, Cheung W, Kol M, Wong H, Shah A, Wagh A, Simpson J, Duke G, Chan P, Cartner B, Hunter S, Laver R, Shrestha T, Regli A, Pellicano A, McCullough J, Tallott M, Kumar N, Panwar R, Brinkerhoff G, Koppen C, Cazzola F, Brain M, Mineall S, Fischer R, Biradar V, Soar N, White H, Estensen K, Morrison L, Smith J, Cooper M, Health M, Shehabi Y, Al-Bassam W, Hulley A, Whitehead C, Lowrey J, Gresha R, Walsham J, Meyer J, Harward M, Venz E, Williams P, Kurenda C, Smith K, Smith M, Garcia R, Barge D, Byrne D, Byrne K, Driscoll A, Fortune L, Janin P, Yarad E, Hammond N, Bass F, Ashelford A, Waterson S, Wedd S, McNamara R, Buhr H, Coles J, Schweikert S, Wibrow B, Rauniyar R, Myers E, Fysh E, Dawda A, Mevavala B, Litton E, Ferrier J, Nair P, Buscher H, Reynolds C, Santamaria J, Barbazza L, Homes J, Smith R, Murray L, Brailsford J, Forbes L, Maguire T, Mariappa V, Smith J, Simpson S, Maiden M, Bone A, Horton M, Salerno T, Sterba M, Geng W, Depuydt P, De Waele J, De Bus L, Fierens J, Bracke S, Reeve B, Dechert W, Chasse M, Carrier FM, Boumahni D, Benettaib F, Ghamraoui A, Bellemare D, Cloutier E, Francoeur C, Lamontagne F, D'Aragon F, Carbonneau E, Leblond J, Vazquez-Grande G, Marten N, Wilson M, Albert M, Serri K, Cavayas A, Duplaix M, Williams V, Rochwerg B, Karachi T, Oczkowski S, Centofanti J, Millen T, Duan E, Tsang J, Patterson L, English S, Watpool I, Porteous R, Miezitis S, McIntyre L, Brochard L, Burns K, Sandhu G, Khalid I, Binnie A, Powell E, McMillan A, Luk T, Aref N, Andric Z, Cviljevic S, Dimoti R, Zapalac M, Mirkovic G, Barsic B, Kutlesa M, Kotarski V, Vujaklija Brajkovic A, Babel J, Sever H, Dragija L, Kusan I, Vaara S, Pettila L, Heinonen J, Kuitunen A, Karlsson S, Vahtera A, Kiiski H, Ristimaki S, Azaiz A, Charron C, Godement M, Geri G, Vieillard-Baron A, Pourcine F, Monchi M, Luis D, Mercier R, Sagnier A, Verrier N, Caplin C, Siami S, Aparicio C, Vautier S, Jeblaoui A, Fartoukh M, Courtin L, Labbe V, Leparco C, Muller G, Nay MA, Kamel T, Benzekri D, Jacquier S, Mercier E, Chartier D, Salmon C, Dequin P, Schneider F, Morel G, L'Hotellier S, Badie J, Berdaguer FD, Malfroy S, Mezher C, Bourgoin C, Megarbane B, Voicu S, Deye N, Malissin I, Sutterlin L, Guitton C, Darreau C, Landais M, Chudeau N, Robert A, Moine P, Heming N, Maxime V, Bossard I, Nicholier TB, Colin G, Zinzoni V, Maquigneau N, Finn A, Kress G, Hoff U, Friedrich Hinrichs C, Nee J, Pletz M, Hagel S, Ankert J, Kolanos S, Bloos F, Petros S, Pasieka B, Kunz K, Appelt P, Schutze B, Kluge S, Nierhaus A, Jarczak D, Roedl K, Weismann D, Frey A, Klinikum Neukolln V, Reill L, Distler M, Maselli A, Belteczki J, Magyar I, Fazekas A, Kovacs S, Szoke V, Szigligeti G, Leszkoven J, Collins D, Breen P, Frohlich S, Whelan R, McNicholas B, Scully M, Casey S, Kernan M, Doran P, O'Dywer M, Smyth M, Hayes L, Hoiting O, Peters M, Rengers E, Evers M, Prinssen A, Bosch Ziekenhuis J, Simons K, Rozendaal W, Polderman F, de Jager P, Moviat M, Paling A, Salet A, Rademaker E, Peters AL, de Jonge E, Wigbers J, Guilder E, Butler M, Cowdrey KA, Newby L, Chen Y, Simmonds C, McConnochie R, Ritzema Carter J, Henderson S, Van Der Heyden K, Mehrtens J, Williams T, Kazemi A, Song R, Lai V, Girijadevi D, Everitt R, Russell R, Hacking D, Buehner U, Williams E, Browne T, Grimwade K, Goodson J, Keet O, Callender O, Martynoga R, Trask K, Butler A, Schischka L, Young C, Lesona E, Olatunji S, Robertson Y, Jose N, Amaro dos Santos Catorze T, de Lima Pereira TNA, Neves Pessoa LM, Castro Ferreira RM, Pereira Sousa Bastos JM, Aysel Florescu S, Stanciu D, Zaharia MF, Kosa AG, Codreanu D, Marabi Y, Al Qasim E, Moneer Hagazy M, Al Swaidan L, Arishi H, Munoz-Bermudez R, Marin-Corral J, Salazar Degracia A, Parrilla Gomez F, Mateo Lopez MI, Rodriguez Fernandez J, Carcel Fernandez S, Carmona Flores R, Leon Lopez R, de la Fuente Martos C, Allan A, Polgarova P, Farahi N, McWilliam S, Hawcutt D, Rad L, O'Malley L, Whitbread J, Kelsall O, Wild L, Thrush J, Wood H, Austin K, Donnelly A, Kelly M, O'Kane S, McClintock D, Warnock M, Johnston P, Gallagher LJ, Mc Goldrick C, Mc Master M, Strzelecka A, Jha R, Kalogirou M, Ellis C, Krishnamurthy V, Deelchand V, Silversides J, McGuigan P, Ward K, O'Neill A, Finn S, Phillips B, Mullan D, Oritz-Ruiz de Gordoa L, Thomas M, Sweet K, Grimmer L, Johnson R, Pinnell J, Robinson M, Gledhill L, Wood T, Morgan M, Cole J, Hill H, Davies M, Antcliffe D, Templeton M, Rojo R, Coghlan P, Smee J, Mackay E, Cort J, Whileman A, Spencer T, Spittle N, Kasipandian V, Patel A, Allibone S, Genetu RM, Ramali M, Ghosh A, Bamford P, London E, Cawley K, Faulkner M, Jeffrey H, Smith T, Brewer C, Gregory J, Limb J, Cowton A, O'Brien J, Nikitas N, Wells C, Lankester L, Pulletz M, Williams P, Birch J, Wiseman S, Horton S, Alegria A, Turki S, Elsefi T, Crisp N, Allen L, McCullagh I, Robinson P, Hays C, Babio-Galan M, Stevenson H, Khare D, Pinder M, Selvamoni S, Gopinath A, Pugh R, Menzies D, Mackay C, Allan E, Davies G, Puxty K, McCue C, Cathcart S, Hickey N, Ireland J, Yusuff H, Isgro G, Brightling C, Bourne M, Craner M, Watters M, Prout R, Davies L, Pegler S, Kyeremeh L, Arbane G, Wilson K, Gomm L, Francia F, Brett S, Sousa Arias S, Elin Hall R, Budd J, Small C, Birch J, Collins E, Henning J, Bonner S, Hugill K, Cirstea E, Wilkinson D, Karlikowski M, Sutherland H, Wilhelmsen E, Woods J, North J, Sundaran D, Hollos L, Coburn S, Walsh J, Turns M, Hopkins P, Smith J, Noble H, Depante MT, Clarey E, Laha S, Verlander M, Williams A, Huckle A, Hall A, Cooke J, Gardiner-Hill C, Maloney C, Qureshi H, Flint N, Nicholson S, Southin S, Nicholson A, Borgatta B, Turner-Bone I, Reddy A, Wilding L, Chamara Warnapura L, Agno Sathianathan R, Golden D, Hart C, Jones J, Bannard-Smith J, Henry J, Birchall K, Pomeroy F, Quayle R, Makowski A, Misztal B, Ahmed I, KyereDiabour T, Naiker K, Stewart R, Mwaura E, Mew L, Wren L, Willams F, Innes R, Doble P, Hutter J, Shovelton C, Plumb B, Szakmany T, Hamlyn V, Hawkins N, Lewis S, Dell A, Gopal S, Ganguly S, Smallwood A, Harris N, Metherell S, Lazaro JM, Newman T, Fletcher S, Nortje J, Fottrell-Gould D, Randell G, Zaman M, Elmahi E, Jones A, Hall K, Mills G, Ryalls K, Bowler H, Sall J, Bourne R, Borrill Z, Duncan T, Lamb T, Shaw J, Fox C, Moreno Cuesta J, Xavier K, Purohit D, Elhassan M, Bakthavatsalam D, Rowland M, Hutton P, Bashyal A, Davidson N, Hird C, Chhablani M, Phalod G, Kirkby A, Archer S, Netherton K, Reschreiter H, Camsooksai J, Patch S, Jenkins S, Pogson D, Rose S, Daly Z, Brimfield L, Claridge H, Parekh D, Bergin C, Bates M, Dasgin J, McGhee C, Sim M, Hay SK, Henderson S, Phull MK, Zaidi A, Pogreban T, Rosaroso LP, Harvey D, Lowe B, Meredith M, Ryan L, Hormis A, Walker R, Collier D, Kimpton S, Oakley S, Rooney K, Rodden N, Hughes E, Thomson N, McGlynn D, Walden A, Jacques N, Coles H, Tilney E, Vowell E, Schuster-Bruce M, Pitts S, Miln R, Purandare L, Vamplew L, Spivey M, Bean S, Burt K, Moore L, Day C, Gibson C, Gordon E, Zitter L, Keenan S, Baker E, Cherian S, Cutler S, Roynon-Reed A, Harrington K, Raithatha A, Bauchmuller K, Ahmad N, Grecu I, Trodd D, Martin J, Wrey Brown C, Arias AM, Craven T, Hope D, Singleton J, Clark S, Rae N, Welters I, Hamilton DO, Williams K, Waugh V, Shaw D, Puthucheary Z, Martin T, Santos F, Uddin R, Somerville A, Tatham KC, Jhanji S, Black E, Dela Rosa A, Howle R, Tully R, Drummond A, Dearden J, Philbin J, Munt S, Vuylsteke A, Chan C, Victor S, Matsa R, Gellamucho M, Creagh-Brown B, Tooley J, Montague L, De Beaux F, Bullman L, Kersiake I, Demetriou C, Mitchard S, Ramos L, White K, Donnison P, Johns M, Casey R, Mattocks L, Salisbury S, Dark P, Claxton A, McLachlan D, Slevin K, Lee S, Hulme J, Joseph S, Kinney F, Senya HJ, Oborska A, Kayani A, Hadebe B, Orath Prabakaran R, Nichols L, Thomas M, Worner R, Faulkner B, Gendall E, Hayes K, Hamilton-Davies C, Chan C, Mfuko C, Abbass H, Mandadapu V, Leaver S, Forton D, Patel K, Paramasivam E, Powell M, Gould R, Wilby E, Howcroft C, Banach D, Fernandez de Pinedo Artaraz Z, Cabreros L, White I, Croft M, Holland N, Pereira R, Zaki A, Johnson D, Jackson M, Garrard H, Juhaz V, Roy A, Rostron A, Woods L, Cornell S, Pillai S, Harford R, Rees T, Ivatt H, Sundara Raman A, Davey M, Lee K, Barber R, Chablani M, Brohi F, Jagannathan V, Clark M, Purvis S, Wetherill B, Dushianthan A, Cusack R, de Courcy-Golder K, Smith S, Jackson S, Attwood B, Parsons P, Page V, Zhao XB, Oza D, Rhodes J, Anderson T, Morris S, Xia Le Tai C, Thomas A, Keen A, Digby S, Cowley N, Wild L, Southern D, Reddy H, Campbell A, Watkins C, Smuts S, Touma O, Barnes N, Alexander P, Felton T, Ferguson S, Sellers K, Bradley-Potts J, Yates D, Birkinshaw I, Kell K, Marshall N, Carr-Knott L, Summers C. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA. 2020 Oct 6;324(13):1317-1329. doi: 10.1001/jama.2020.17022.
Angus DC, Berry S, Lewis RJ, Al-Beidh F, Arabi Y, van Bentum-Puijk W, Bhimani Z, Bonten M, Broglio K, Brunkhorst F, Cheng AC, Chiche JD, De Jong M, Detry M, Goossens H, Gordon A, Green C, Higgins AM, Hullegie SJ, Kruger P, Lamontagne F, Litton E, Marshall J, McGlothlin A, McGuinness S, Mouncey P, Murthy S, Nichol A, O'Neill GK, Parke R, Parker J, Rohde G, Rowan K, Turner A, Young P, Derde L, McArthur C, Webb SA. The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design. Ann Am Thorac Soc. 2020 Jul;17(7):879-891. doi: 10.1513/AnnalsATS.202003-192SD.
Related Links
Access external resources that provide additional context or updates about the study.
global REMAP-CAP Study Website
EU REMAP-CAP Study Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2015-002340-14
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
602525
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
16/631
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
APP1101719
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
158584
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
2023-507889-89-00
Identifier Type: CTIS
Identifier Source: secondary_id
965313
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
U1111-1189-1653
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.